Iressa Relabeling Reflects Competing Risk/Benefit Interests – CDER’s Galson
Executive Summary
FDA's decision to limit the use of Iressa (gefitinib) is indicative of the agency's attempt to incorporate competing interests in a risk/benefit analysis, Center for Drug Evaluation & Research Acting Director Steven Galson said June 21